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Abstract 1 
Identifying appropriate animal models is critical in developing translatable in vitro and in vivo systems 2 
for therapeutic development and investigating disease pathophysiology. These animal models should 3 
have direct biological and translational relevance to the underlying disease they are supposed to mimic. 4 
Aging dogs naturally develop a cognitive decline in many aspects including learning and memory, but 5 
also exhibit human-like individual variability in the aging process. Neurodegenerative processes that 6 
can be observed in both human and canine brains include the progressive accumulation of β-amyloid 7 
(Aβ) found as diffuse plaques in the prefrontal cortex, including the gyrus proreus, the hippocampus, 8 
and in the cerebral vasculature. A growing body of epidemiological data shows that human patients 9 
with neurodegenerative diseases have concurrent intestinal lesions, and histopathological changes in 10 
the gastrointestinal (GI) tract occurs decades that evolve before neurodegenerative changes. Gut 11 
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 2
microbiome alterations also have been observed in many neurodegenerative diseases including 12 
Alzheimer’s and Parkinson’s diseases, and inflammatory CNS diseases. Interestingly, only recently has 13 
the dog gut microbiome been recognized to more closely resemble in composition and in functional 14 
overlap with the human gut microbiome as compared to rodent models. This article aims to review the 15 
physiology of the gut-brain axis (GBA), and its involvement with neurodegenerative diseases in dogs 16 
and humans. Additionally, we outline the advantages and disadvantages of traditional in vitro and in 17 
vivo models and discuss future research directions investigating major human neurodegenerative 18 
diseases such as Alzheimer’s and Parkinson’s diseases using dogs. 19 
 20 
1. Introduction 21 
The gut-brain axis (GBA) is a highly complex bidirectional interactive system, mediated by hormonal, 22 
immunological and neural signals between the gut and the brain1. A growing body of evidence suggests 23 
that the gut microbiota have profound impacts on the neurodevelopmental processes and brain 24 
function2,3. Specifically, dysregulation of GBA cross-talk is associated with  metabolic syndrome4,5 and 25 
psychiatric disorders such as depression, anxiety, autism, Parkinson’s disease (PD), and Alzheimer’s 26 
disease (AD)6,7. In turn, these disorders are also frequently associated with alterations in  gut 27 
microbiota composition and  function which may in turn contribute to  disruption of molecular 28 
interactions  between the gut and brain8,9. 29 
 30 
The GBA is formed by the central nervous system (CNS), the enteric innervation that includes extrinsic 31 
fibers of the autonomous nervous system (ANS) and intrinsic neurons of the enteric nervous system 32 
(ENS), the hypothalamic pituitary adrenal (HPA)-axis and the intestinal microbiota10. The extrinsic 33 
innervations of the gastrointestinal (GI) tract connect the gut with the brain through vagal and spinal 34 
fibers, while the brain sends efferent sympathetic and parasympathetic fibers to the GI tract10–12. The 35 
HPA-axis is considered the main regulator of the stress response13. Furthermore, the HPA-axis 36 
regulates different body processes including alimentary function during digestion [Ref]. Corticotrophin-37 
releasing factor (CRF) released by the hypothalamus and different proteins within this family (e.g., 38 
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CRF, urocortin 1-3) are known to affect GI tract function, i.e. intestinal motility14, permeability15, and 39 
inflammation16. Specifically, changes in the gastroduodenal motility induced by urocortin administration 40 
were noted in conscious rats and this study also suggested that the vagal pathway may mediate the 41 
central action of urocortin14. The rats subjected to stress (i.e., water avoidance stress) and 42 
corticosterone injections exhibited region-specific decreases in epithelial tight junction protein levels in 43 
the colon and increased colon epithelial permeability as measured by low molecular weight 44 
macromolecules15. In addition, cortisol and the proinflammatory cytokines interleukin (IL)-6 and IL-8 45 
were founds to be elevated in patients with IBS16.  46 
Both clinical and experimental evidence suggests that enteric microbiota contribute to regulating the 87 
communication and function of the GBA, including the ability to modulate immune mediators (e.g., 88 
cytokines and chemokines)17. The GBA interacts not only locally with intestinal cells and ENS, but also 89 
directly with CNS through neuroendocrine and metabolic pathways18. Furthermore, microbiota can 90 
influence ENS activity by producing small molecules that can act as local neurotransmitters, such as γ-91 
aminobutyric acid (GABA), amino-acid derivatives (e.g. serotonin, melatonin, and histamine) and fatty-92 
acid derivatives (e.g.acetylcholine)19 and by generating a biologically active form of catecholamines 93 
(i.e., dopamine, norepinephrine) in the lumen of the gut20. The ENS is also targeted by bacterial 94 
metabolites such as short-chain fatty acids (SCFAs), including butyric acid, propionic acid and acetic 95 
acid, which act to stimulate sympathetic nervous system21, mucosal serotonin release22 and to 96 
influence memory and the learning process23,24.  97 
 98 
2. GBA in Neurodegenerative Diseases 99 
Dysfunction of the gut microbiota-brain axis has been associated  with depression and anxiety, as well 100 
as neurodevelopmental disorders such as autism, PD, and AD8,25,26.  101 
 102 
Alzheimer’s Disease 103 
AD is a neurodegenerative syndrome accompanied by progressive dementia and histologically 104 
associated with the accumulation of cerebral amyloid angiopathy (CAA), which is plaques composed of 105 
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misfolded β-amyloid (Aβ) fibrils and oligomers, as well as neurofibrillary tangles consisting of 106 
hyperphosphorylated tau protein in the cerebral cortex, locus coeruleus, and hippocampus27. Aβ fibrils 107 
accumulation leads to demyelination, neuronal cell death, CNS impairment, cognitive dysfunction, and 108 
ultimately death28–30.   109 
 110 
One hypothesis for pathogenesis of GBA in neurodegenerative diseases is dysbiosis, which occurs as 111 
a result of antibiotic exposure31, dietary changes32, probiotics33, or a  variety of other disease 112 
conditions34,35. Specifically, various studies have shown  an association between dysbiosis and 113 
aggregation of Aβ peptides in intestinal epithelial cells36,37 and ENS38,39. Different components of the 114 
microbiota, such as bacteria, can excrete immunogenic mixture of functional lipopolysaccharides 115 
(LPSs), amyloids, and exudates from their outer membranes into the local intestinal environment40,41. 116 
Amyloids and LPSs  are usually soluble, although they can polymerize and form insoluble fibrous 117 
protein aggregates, leading to stimulation of oxidative stress and cross-seeding of further protein 118 
aggregation42,43. For example, E.coli endotoxin was shown to enhance the formation of Aβ fibrils in an 119 
in vitro model44. Also, another study showed that co-incubation of Aβ peptide with LPS potentiates 120 
amyloids fibrillogenesis44, and systemic injection of LPS in wile-type and transgenic AD mice result in 121 
greater amyloids deposition and tau pathology46–49. Moreover, studies suggest that the structural 122 
overlaps in the bacterial amyloid proteins to human Aβ may induce molecular mimicry, an immune 123 
response against the self-antigens stimulated by a foreign antigen sharing structural similarities with 124 
self-antigens, causing greater inflammatory responses to cerebral Aβ due to altered gut microbiota32–34.   125 
Another hypothesis is “prion concept” given the fact that many neurodegenerative diseases exhibit 126 
accumulation of fibrillary, misfolded protein and its propagation similar of what has been seen in 127 
prionopaties45. Prionopathy also involves GBA and the local immune system when prions accumulate in 128 
follicular dendritic cells within Peyer’s patches and other lymphoid follicles once entering into the 129 
intestinal epithelium46. Interestingly, a study with a senescence-accelerated mouse model, systemic 130 
senile amyloid proteins were identified in Peyer’s patches47 Combining these findings, then, by 131 
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interacting with dendritic cells, the misfolded protein might be transported to ENS then ultimately 132 
spreading to the CNS46 and this could explain the pathogenesis in AD with Aβ accumulation. A 133 
significant amount of functional amyloid was shown to be generated by certain bacterial strains, 134 
including Escherichia coli, Bacillus subtilis, Salmonella typhimurium, S. enterica, and Staphylococcus 135 
aureus, and may contribute to the pathology of AD through the accumulation of misfolded Aβ oligomers 136 
and fibrils40,48. Some bacterial species, such as Lactobacillus spp. and Bifidobacterium spp. (both gram-137 
positive facultative anaerobic or microaerophilic bacteria) are able to metabolize glutamate to produce 138 
GABA, the major inhibitory neurotransmitter28. These observations  suggest that alteration of the gut 139 
microbiota can compromise the endogenous production of GABA28. Indeed, alteration of GABA 140 
signaling is  linked to cognitive impairment, AD, anxiety and depression45,49–51. Alternatively,  gut 141 
bacteria  can affect the peripheral nerve function including ENS, is by its metabolites such as short-142 
chain fatty acid (SCFAs)21. The SCFAs, such as butyric acid, propionic acid, and acetic acid, are 143 
produced by a bacterial fermentation of dietary ﬁber in the colon. They not only are a part of the critical 144 
energy source for colonic epithelial cells, but also can stimulate sympathetic nervous system and 145 
release serotonin, then ultimately influence the CNS processes including memory and learning22. 146 
Importantly, lower levels of SCFAs are shown to negatively affect immune responses, epithelial cell 147 
growth, and  possibly affect the function of both the central and peripheral nervous systems52,53.  148 
 149 
Parkinson’s Disease 150 
Patients with PD show  classic motor symptoms such as asymmetric resting tremor that are caused 151 
primarily by the loss of dopamine resulting from degeneration and death of dopaminergic neurons in the 152 
midbrain2. The pathophysiology in PD neurodegeneration have not been definitely established; 153 
however, abundant evidence suggests that there are neuroinflammation and glial cell activation in PD 154 
patients. Proinflammatory signaling molecules including cytokines (i.e. IL-1β, IL-6, and TNF-α) or 155 
enzymes (i.e. nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2)), and oxidative stress are 156 
considered key mechanisms that contribute to neurodegeneration and cell death in PD54.  157 
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Another highly relevant factor in PD pathogenesis is α-synuclein (αSYN), which is the protein present in 158 
numerous cell types throughout the body with increased expression at presynaptic terminals of 159 
neurons55. This protein is highly soluble and regulate the release of synaptic vesicles which contains 160 
important neurotransmitters55. The αSYN is also expressed as a normal component of the ENS, and it 161 
can be detected in submucosal neuronal structures in the intestinal tissues in a large percentage of 162 
neurologically intact humans56–58. However, under certain circumstances59, αSYN adopts a β-sheet 163 
structure, loses its membrane-binding capacity, therefore leads to aggregation of such misfolded 164 
proteins, which ultimately leads to the histological hallmark of PD-Lewy neurites and Lewy bodies in 165 
especially dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus 166 
coeruleus59. Aggregates of misfolded αSYN impair mitochondrial complex I activity, reduce 167 
mitochondrial function and lead to oxidative stress in the neuron54–56. Individuals with mutations in the 168 
αSYN gene SNCA or multiplication of wild-type SNCA gene allele are known to develop early-onset, 169 
rapidly-progressive PD60. PD pathology that involves αSYN spreads from the ENS to the CNS by trans-170 
synaptic cell-to-cell transmission in intact sympathetic and parasympathetic nervous systems55,56, which 171 
is the foundation of “prion concept” in PD pathophysilogy61.  Interestingly, studies have reported distinct 172 
αSYN immunoreactivity in intestinal biopsies taken from clinically normal individuals who would later 173 
develop PD57,62,63, indicating that abnormal enteric αSYN is present before CNS neurodegeneration has 174 
advanced sufficiently to produce motor symptoms2. Various clinical gastrointestinal signs or the 175 
characteristic PD ENS pathology often occur before function of the brain is affected, with constipation 176 
being the most common GI complaint in PD57. This is likely due to  prolonged intestinal transit time, 177 
which has been reported to affect both the small intestine64 and the colon in PD patients65. It has been 178 
clearly shown that constipation can manifest as a pre-motor symptom years before CNS 179 
degeneration66,67. In addition, a growing body of data indicates that PD patients have increased 180 
intestinal permeability compared to healthy controls68. Interestingly, studies also suggest that there are 181 
increased risk of developing dementia69 or Parkinson’s disease70 in patients with irritable bowel 182 
syndrome.  183 
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In recent years, the relationships between intestinal microbiota and PD pathology and their link to 184 
deranged  GI motility have been studied, and some of the reported differences include decrease in 185 
Prevotella spp. and Clostridium spp. in PD patients71,72. These intestinal bacteria are prominent 186 
producers of SCFAs, such as butyrate as well as folate (vitamin B9) and thiamine (vitamin B1) which 187 
are important for maintenance of epithelial barrier function71,72. Interestingly, all of these SCFAs are 188 
associated with the amelioration of PD pathology72–74. For molecular mimicry in the pathophysiology of 189 
PD, Tobacco Mosaic virus (TMV)43 has been implicated but needs more investigation to make absolute 190 
conclusion.  191 
 192 
3. Experimental Approaches to Investigating the GBA 193 
Both static and dynamic in vitro models have been utilized to advance the understanding of pathogy of 194 
the GBA in neurodegenerative diseases. The schematic of the major benefits and disadvantages are 195 
summarized in Figure 2. It is important to note that cognitive dysfunction is a highly prevalent not only in 196 
AD but also in the non-motor symptoms of PD75. In in vivo model section, main focus will be on in vivo 197 
AD models; however, findings from these in vivo models for cognitive impairment would be relevant to 198 
both AD and PD. The summaries of similarity and differences between clinical and histological 199 
differences are stated in Figure 3.  200 
 201 
3.1. In vitro Models 202 
Static Systems 203 
Development of useful in vitro model is critical for elucidating pathophysiology and developing effective 204 
therapies especially in the neurodegenerative diseases. Only about 7% of investigational agents tested 205 
in phase III trials progress into the market in neurology. This is worse than  the average of 11% of drugs 206 
marketed for all disease categories76,77.  207 
 208 
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The blood-brain barrier (BBB), a unique compartment that constitutes the interface between the 209 
peripheral circulation and the CNS, is the key compartment to understand the GBA78. The BBB not only 210 
supplies nutrients to the CNS, but also removes waste products (such as urea or potassium) and, 211 
prevents blood-borne pathogens and toxic products from harming the brain78. The most unique 212 
characteristic of the BBB is the network of tight junctions between individual capillary endothelial cells 213 
that lack fenestration with reduced capacity for pinocytosis, which ultimately maintains the molecular 214 
integrity of BBB79.  215 
 216 
Attempts to craft an in vitro model to recapitulate the complexity of the BBB has been attempted and 217 
the most traditional BBB in vitro culture models, include brain microvascular endothelial cells and 218 
astrocytes in a static Transwell culture66. Leveraging its similarity with conventional 2-dimensional (2D) 219 
culture system and relative simplicity, the Transwell BBB system has been widely used in a research 220 
setting66; however, it does not provide the shear forces that are critical for maintenance of endothelial 221 
polarization and tight junction (TJ) formation66. These critical shortcomings result in endothelial 222 
permeability that is higher in this model than physiologically seen, which leads to overestimation of 223 
compounds that poorly penetrate across the BBB in vivo (e.g., sucrose) can now readily diffuse across 224 
the endothelial monolayer in the static model80.  225 
Additionally, current in vitro models include brain microvascular endothelial cell (BMVEC) and astrocyte 226 
elements as the BBB models do not replicate the close physiological cross-talk between pericytes and 227 
the capillary endothelium81. Significant improvements were seen in these BBB models with addition of 228 
intraluminal flow in a hollow fiber in vitro model and the presence of astrocytes on the abluminal 229 
surface, which accomplished more physiologically realistic polarization of the endothelial cells and 230 
strengthens the integrity of TJs82.  231 
 232 
Attempts were made to study the GBA  using a transwell culture system as also83. This system includes 233 
only a few components of the GBA and it is important to note that Caco-2 cells, immortal cells from 234 
human epithelial colorectal adenocarcinoma, are used to model the enteric epithelial cells in this 235 
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system.83 Given these collective limitations as well as the lack of integration of microbiome/ENS in the 236 
in vitro system, the results derived from these studies are of questionable  translational relevance.  237 
 238 
Dynamic Model Systems Using Microfluidics 239 
It is only recent that a novel technology called an organ-on-a-chip (organ-OAC) has emerged84,85. The 240 
microfluidic device contains microtubing that allow continued flow of media and comprises of multiple 241 
cell culture channels  allowing  co-culture of different cell types86,87  The multiple small channels 242 
compartmentalized by a ﬂexible or a rigid porous membrane allow this innovative model system to 243 
recapitulate the tissue-tissue interface88.  244 
The Gut-OAC (GOAC), which contains multiple-compartment microenvironment, allows researchers to 245 
investigate intercellular interactions between intestinal epithelium, immune components, and living gut 246 
bacteria or probiotics86,89. This technology can be used to investigate the contributions of the gut 247 
microbiome, probiotics, or compounds on  intestinal pathophysiology and to elucidate 248 
pathophysiologies of the  in vitro environment that are  not possible using conventional/static in vitro 249 
systems86.  250 
Recently, a BBB-OAC was established and showed physiological barrier functions90, using  ENS and 251 
enteroendocrine cells (EEC)-OAC combined together to assess the GBA microenvironment91. 252 
Advancement in bioengineering techniques will allow incorporating multiple compartments in one in 253 
vitro system such as a GBA-OAC92,93. Despite the great promise of the Organ Chip technology, the 254 
transfer of cells from a macroscopic environment (e.g., well-plates) to a microﬂuidic system requires a 255 
signiﬁcant revision and optimization of cell culture protocols. In fact, multiple factors distinguish 256 
microﬂuidic from macroscopic cell cultures, such as different culture channel surfaces (hydrophobic vs 257 
hydrophilic) and the need of reduced media volumes which can magnify the air bobbles blocking the 258 
cell-medium contact within the culture channel72. Despite these limiting factors including  the technology 259 
being labor intensive, GOACs are a fast-growing model system  which holds greater potential to 260 
investigate primary GI diseases and the GBA microenvironment. environment. It is important to note 261 
that our group recently established canine primary enteroid and colonoid culture system94,95. This is 262 
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canine intestinal stem cell (ISC) culture system which faithfully mimic physiologic structure and function 263 
of in vivo intestines96. We can establish such in vitro system from both healthy and diseased 264 
individuals, which allow investigation of the pathophysiology and treatment effect using this model. 265 
Integration of canine primary enteroid/colonoid to the GOAC system is a primary area of research for 266 
the further drug development currently being investigated by our group. The GOAC technology can 267 
provide alternative and translatable methods for drug absorption, toxicity, and efficacy screenings, and 268 
holds a promise to explore avenues of personalized therapy for GI and neurologic diseases in the near 269 
future94. 270 
 271 
3.2. In vivo animal Models 272 
One of the main obstacles in studying the GBA is the lack of an animal model system that successfully 273 
replicates a healthy or diseased individual's gut microbiome. Another obstacle is that the current rodent 274 
models for neurodegenerative diseases only allow investigation of short-term exposure to suspected 275 
triggers. Investigation on the GBA effect with certain diets or probiotics requires studies in natural 276 
models to have translational significance. Although the traditional rodent models for neurodegenerative 277 
diseases have been and will be allowing investigators to assess a targeted question (i.e. transgenic 278 
mice with deleted gene and how such gene deletion affects the pathology), it is critical to realize the 279 
current flaws in utilizing such in vitro models in pharmaceutical development, especially after looking at 280 
the poor success rate in drug discovery76,77. Since rodent diets differ substantially from that of humans, 281 
making comparisons between human and mouse gut microbiota studies is inherently difficult97,98. Mice 282 
preferentially consume grains and cereals, which are low in ascorbic acid, and they hold the ability to 283 
synthesize this essential cofactor while humans have lost this ability99. Also, presumably because of 284 
their ancestors’ ingestion of different xenobiotics, mice and humans have different complements of 285 
cytochrome P450 enzymes and different patterns of xenobiotic metabolism100,101. At least in part for this 286 
reason, toxicology testing in mice has been a poor predictor of human toxicity102. While studies have 287 
been performed using conventional mouse models to investigate diseases involving the GBA, the 288 
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alterations seen in the intestinal bacterial populations in mice are usually not reciprocated by human 289 
data103.  290 
 291 
Another factor as to why rodent models do not mirror human pathophysiology is due to the contrived 292 
nature of these induced disease models. As discussed before, AD is histologically characterized by 293 
progressive dementia and the presence of CAA due to Aβ aggregates in the walls of cerebral 294 
vessels29,104. However, rodent models do not produce human sequence Aβ naturally105 which limits 295 
their investigative utility. Transgenic mouse models with over expressing the mutant human amyloid 296 
precursor protein (APP) alone or combined with transgenic presenilin 1 (PS1) and presenilin 2 (PS2) 297 
gene have secondary Aβ plaque formation in the brain histologically mimicking AD106. However, these 298 
transgenic mouse models naturally have cellular and behavioral resistance to Aβ pathology and 299 
therefore do not develop the extensive neuronal loss seen in the AD patients107. Also, there is a 300 
fundamental difference in the anatomic folding of the cerebral cortex; with humans having a  301 
gyrencephalic brain and  rodents having a  lissencephalic brain108. 302 
 303 
Accumulated data shows that the dog provides a complementary model system to the transgenic 304 
mouse model to investigate the physiology of aging associated with  neurodegenerative diseases, and 305 
ultimately to develop therapeutics109. The dog is a particularly relevant species since it shares similar 306 
environmental, genomic, and intestinal physiologic features with humans110. Canine natural models also 307 
offer additional predictive validity before transitioning to human clinical trials in many different diseases 308 
including neurodegenerative diseases111. A recent study suggests that in the process of domestication 309 
in dogs, genes associated with digestion have been selected to thrive on a starch-rich diet unlike 310 
wolves and more similar to humans112. Interestingly, a study with polynomial regression analysis 311 
showed that middle aged beagles between 5 and 9 years show similar aging process to humans 312 
between 40 and 60 years regarding cognitive function, while beagles over 9 years are similar to 313 
humans over 66 years113.  314 
 315 
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3.3. Canine Models as Natural Models for Neurodegenerative Diseases: similarities and 316 
differences 317 
Aged dogs with canine cognitive dysfunction (CCD) spontaneously develop varying degrees of 318 
progressive cognitive decline and particular neuropathological features, similar to  changes seen in 319 
AD114. CCD dogs show similar abnormal MRI or gross histological findings as AD patients including 320 
cortical atrophy115,116 and ventricular enlargement117. Neurodegenerative changes which have been 321 
identified in the aged dog brain are similar to those seen in AD, including  diffuse Aβ plaque 322 
deposition110,118 and accompanied CAA119, together with  neuronal loss120 and dysfunction of  323 
neurotransmitter systems121. Moreover,  another major neuropathological hallmark of AD besides Aβ 324 
plaques is hyperphosphorylated tau proteins62 and they are rarely found in aged dogs compared to that 325 
in human AD122. Interestingly, one of the biomarkers of AD, plasma Aβ42 level, is also increased in CCD 326 
dogs123. This biomarker will allow early identification of those patients that are most likely to develop AD 327 
in human (or CCD in dogs) and possibly amenable to early intervention to slow down disease 328 
progression. 329 
 330 
Canine multiple system degeneration (CMSD) is a fatal, familial movement disorder first described in 331 
Kerry Blue Terriers124, then in Chinese Crested dogs125, and these breeds could be considered as 332 
natural models for PD. Affected dogs are normal until 3–6 months of age, when they develop cerebellar 333 
ataxia125. This progresses to akinesia (i.e., impairment in voluntary movement) and severe postural 334 
instability ultimately necessitating euthanasia by 1–2 years of age125. Histologically, CMSD is 335 
characterized by loss of cerebellar Purkinje cells followed by degeneration of the olivary nucleus, 336 
substantia nigra, putamen, and caudate nucleus124,126. Interestingly, the CMSD locus includes a 337 
segment that contains PARK2, the gene for parkin, and mutations in human PARK2 is known to cause 338 
familial PD, which has clinical and pathological similarities to CMSD125.  339 
 340 
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In addition to the similarity in clinicopathological changes in human and canine neurodegenerative 341 
diseases, a recent study showed the similarity in their microbiome and the diet response between dogs 342 
and humans compared to traditional rodent models127.   343 
 344 
No animal models are perfect and it is recognized that the canine model has limitations as well. For 345 
example, it has been recently shown that dogs lack aldehyde oxidases (AOXs) which catalyze the 346 
oxidation of aldehydes or N-heterocycles metabolism128. This fact has physiological, pharmacological, 347 
and toxicological relevance because AOXs are believed to represent an important metabolic system 348 
capable of oxidizing a large array of endogenous and exogenous substrates129. Also, human and 349 
canine have different CYP3A isoforms (i.e., canine CYP3A12 is equivalent to human CYP3A4) and it is 350 
important to recognize the species differences when interpreting permeability, toxicity, and metabolism 351 
analysis using  both in vitro and in vivo system130. A parallel assessment between in vivo expressions of 352 
such transporters and receptors and those found in in vitro system is required to demonstrate   353 
translatability. Also, it possible that  differences in activity and substrate specificity/inhibitors and 354 
inducers are observed in the dog ; therefore, utilizing in vitro systems from multiple different species 355 
would allow us to supplement other in vitro systems that might not completely mimic human 356 
physiology130. 357 
 358 
4. Therapeutic approaches for modulating the GBA and value of the canine model in AD 359 
In this section, we focus on therapeutic approaches for modulation of the GBA with a special emphasis 360 
on AD. However, similar approaches could be of benefit for the management of non-motor symptoms of 361 
PD, such as cognitive dysfunction.  362 
 363 
4.1. Dietary interventions 364 
Many human epidemiological studies have shown that nutrition and other lifestyle factors affect 365 
cognitive function and some of those factors show ameliorating effect in developing AD131. Decreased 366 
microbial diversity in the GI tract induced by high-fat diets has been associated with development of 367 
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various neurological diseases including AD and PD132. The multi-hit hypothesis in neurodegenerative 368 
diseases is that certain diets lead to dysbiosis133, then bacterial amyloids (e.g., molecular mimicry) 369 
activate AD pathogenesis by providing immunostimulatory misfolded amyloids, while the gut 370 
microbiome enhances inflammatory responses to cerebral accumulation of Aβ43. This suggests that 371 
modulating the gut microbiome through specific dietary interventions with prebiotics and/or probiotics 372 
can be an effective strategy to correct dysbiosis, reduce chronic gut inflammation and Aβ aggregation  373 
to slow down the progression of AD.   374 
 375 
The ketogenic diet, which has anticonvulsant properties, was developed in the 1920s to mimic 376 
physiological state seen in prolonged fasting134. The traditional ketogenic diet is very high in fat and low 377 
in carbohydrates, which shifts the energy balance to lipolysis (i.e., to metabolize body fat), which leads 378 
to ketogenesis, which is β-oxidation of fatty acids, and ultimately to the production of acetoacetate, β-379 
hydroxybutyrate, and acetone135. These substances can easily cross the BBB and be used as 380 
precursors for the generation of adenosine triphosphate (ATP)135. Several mechanisms exist for 381 
explaining how  ketone bodies exert anti-convulsant actions,136 including  increased ATP production, 382 
altered brain pH affecting neuronal excitability, and/or their direct inhibitory effects on ion channels137. 383 
Since  some glucose is required for the synthesis and homeostasis of glutamate, which is the most 384 
abundant excitatory neurotransmitter, a ketogenic diet that is very low in carbohydrates may prevent 385 
seizures by minimizing the formation of the excitatory neurotransmitter that could lead to seizure 386 
activities138. Ketones are also structurally similar to GABA, which is an inhibitory neurotransmitter, and 387 
may have direct anticonvulsant or even antiepileptogenic effects139  388 
 389 
Recent findings further suggest that caloric restriction also prevents age-related neuronal damage and 390 
may be useful in the prevention and treatment of AD140. Several mechanisms for its beneficial effects of 391 
caloric restriction include anti-inflammatory properties, reduction of oxidative stress, promotion of 392 
synaptic strength as well as induction of various neuroprotective factors140. Caloric restriction also 393 
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induces fatty acids oxidation (FAO) in intestinal stem cells, which are known to be reduced with 394 
aging141.  395 
 396 
Interestingly, some of these dietary interventions have been investigated in dogs. Similar positive 397 
effects were observed with ketogenic diets incorporating medium chain triglyceride (MCT) in epileptic 398 
dogs with up to <50 % reduction in seizure activity142, and now commercially available. Aged dogs 399 
receiving MCT diets showed significantly improved mitochondrial function, decreased APP levels, and a 400 
trend towards a decrease in total Aβ levels most prominent in the parietal lobe143.  401 
Lifestyle and nutrition are suspected to play a role in the development of CCD in dogs and intensive 402 
training on cognitive tasks during their lifetime as well as supplementation of food with antioxidants can 403 
delay the onset or mitigate cognitive decline144. Similarly, aged dogs fed an antioxidant-enriched diet 404 
had significantly less age-dependent cognitive impairment than aged dogs fed the control diet144.  405 
 406 
4.2. Probiotics 407 
Probiotics are living microorganisms with potential health benefits to the host38. As discussed before, 408 
GABA is the major inhibitory neurotransmitter in the CNS, and it is produced by L. brevis and B. 409 
dentium via glutamate metabolism145. Postmortem studies of the cortical areas of AD patients have 410 
shown reduced frontal, temporal, and parietal GABA concentrations146. There are numerous  studies in 411 
rodent models assessing the impact of probiotics on cognitive behavior147.  Stress-induced memory 412 
impairment in mice can be restored by administering a daily treatment of probiotics (L. rhamnosus 413 
R0011 + L. helveticus R0052)147. Treatment with L. fermentum NS9 mitigated an ampicillin-induced 414 
spatial memory impairment and inhibited the ampicillin-induced reductions in N-methyl-D-aspartate 415 
(NMDA) receptor, which is a glutamate receptor as well as an ion channel, expression in rats148. The 416 
probiotic L. helveticus NS8 was also shown to significantly mitigate cognitive impairment in the 417 
hippocampus of rats149. Treatment with VSL#3 was shown to induce significant increase in intestinal 418 
Actinobacteria and Bacterioidete), which correlated with ameliorated age-related deficit in VSL#3-419 
treated aged rats150. More importantly, a recent randomized, double-blind, and controlled clinical trial 420 
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demonstrated that a mixture of probiotics (L. acidophilus + L. casei + B. bifidum + L. fermentum) 421 
consumption for 12 weeks had a positive effect on cognitive function and some metabolic statuses in 422 
AD patients151. Dysbiosis assessment in CCD dogs and potential therapeutic benefit of probiotics in 423 
CCD dogs are needed to further investigate parallel therapeutic options in cognitive dysfunction in both 424 
humans and dogs. 425 
 426 
5. Conclusions and perspectives 427 
The collective scientific evidence supports the hypothesis that the GBA plays a critical role in the 428 
pathophysiology of various neurodegenerative diseases, such as AD and PD. Murine models are 429 
informative tools to investigate specific hypotheses in many research settings; however, given the 430 
induced or genetically modified nature of their disease state, there has been very little translatability in 431 
testing of new therapeutic interventions to humans. Aged dogs with CCD syndrome naturally 432 
recapitulate the key features of human aging, making them particularly useful for investigating 433 
preventative or therapeutic interventions particularly for AD. Also, the dog gut microbiome has been 434 
shown to overlap more with the human microbiome compared to that of conventional murine model.   435 
 436 
The most recent analyses suggest that one of the most expensive therapeutic areas in terms of drug 437 
research and discovery (R&D) costs is neurology152. This is because drugs in this category experience 438 
particularly lower success rates and that approximately 7% of investigational agents tested in phase III 439 
trials make it onto the market in neurology76. A barrier to achieving better attrition rate in neurology drug 440 
R&D is the lack of utilization of good natural models of true patient benefit. As we discussed earlier, the 441 
dog is a particularly relevant species since it shares multiple features with humans. Also, CCD dogs 442 
can be utilized as a natural model for AD as well as PD, and novel therapeutic trials can be done prior 443 
to entering human trials to assess its effect (i.e. reverse extrapolation). It is important to note that 444 
because organoids are derived from individuals with different genotypes and environmental risk factors, 445 
they are a highly relevant model system for personalized therapy. Integration of such organoid culture 446 
system with GOAC technology could hold natural or patient-speciﬁc disease characteristics and could 447 
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be utilized to screen for potential therapeutic discovery during early exploratory R&D phase. In the near 448 
future, combination of data from GOAC models and clinical trials using dogs as natural disease models, 449 
as well as bioinformatics, such collaborate studies can be used not only to screen novel therapeutics 450 
but also to predict the outcome of novel therapeutics prior to entering human trials to assess its effect 451 
(i.e., reverse extrapolation).   452 
 453 
CONFLICT OF INTEREST:  454 
JM, AJ, KA, and HJK are founders of a company, 3D Health Solutions, which is offer canine intestinal 455 
oganoid culture as an assay system to improve the selection of the most promising candidate in 456 
pharmaceutical research and development. YMA is a recent addition to the company.  457 
 458 
References 459 
1. Rhee, S. H., Pothoulakis, C. & Mayer, E. A. Principles and clinical implications of the brain–gut–enteric 460 
microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 6, 306–314 (2009). 461 
2. Houser, M. C. & Tansey, M. G. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s 462 
disease pathogenesis? NPJ Park. Dis. 3, (2017). 463 
3. Sampson, T. R. et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of 464 
Parkinson’s Disease. Cell 167, 1469-1480.e12 (2016). 465 
4. Grasset, E. et al. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance 466 
through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metab. 25, 1075-1090.e5 (2017). 467 
5. de Lartigue, G., de La Serre, C. B. & Raybould, H. E. Vagal afferent neurons in high fat diet-induced obesity; 468 
intestinal microflora, gut inflammation and cholecystokinin. Physiol. Behav. 105, 100–105 (2011). 469 
6. Sampson, T. R. et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of 470 
Parkinson’s Disease. Cell 167, 1469-1480.e12 (2016). 471 
7. Zhang, T. et al. Comparative Epidemiological Investigation of Alzheimer’s Disease and Colorectal Cancer: The 472 
Possible Role of Gastrointestinal Conditions in the Pathogenesis of AD. Front. Aging Neurosci. 10, (2018). 473 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 18 
8. Esteve, E., Ricart, W. & Fernández-real, J. Gut microbiota interactions with obesity, insulin resistance and type 474 
2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr. Opin. Clin. Nutr. Metab. Care 14, 483–475 
490 (2011). 476 
9. O’Mahony, S. M., Hyland, N. P., Dinan, T. G. & Cryan, J. F. Maternal separation as a model of brain–gut axis 477 
dysfunction. Psychopharmacology (Berl.) 214, 71–88 (2011). 478 
10. Grenham, S., Clarke, G., Cryan, J. F. & Dinan, T. G. Brain–Gut–Microbe Communication in Health and 479 
Disease. Front. Physiol. 2, (2011). 480 
11. Browning, K. N. & Travagli, R. A. Central Nervous System Control of Gastrointestinal Motility and 481 
Secretion and Modulation of Gastrointestinal Functions. Compr. Physiol. 4, 1339–1368 (2014). 482 
12. Foster, J. A., Rinaman, L. & Cryan, J. F. Stress & the gut-brain axis: Regulation by the microbiome. 483 
Neurobiol. Stress 7, 124–136 (2017). 484 
13. Tsigos, C. & Chrousos, G. P. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. 485 
Psychosom. Res. 53, 865–871 (2002). 486 
14. Kihara, N. et al. Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor 487 
activity in conscious rats. Am. J. Physiol.-Gastrointest. Liver Physiol. 280, G406–G419 (2001). 488 
15. Zheng, G. et al. Corticosterone mediates stress-related increased intestinal permeability in a region-489 
specific manner. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 25, e127-139 (2013). 490 
16. Dinan, T. G. et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma 491 
cytokines as a potential biomarker? Gastroenterology 130, 304–311 (2006). 492 
17. Moloney, R. D., Desbonnet, L., Clarke, G., Dinan, T. G. & Cryan, J. F. The microbiome: stress, health and 493 
disease. Mamm. Genome 25, 49–74 (2014). 494 
18. Carabotti, M., Scirocco, A., Maselli, M. A. & Severi, C. The gut-brain axis: interactions between enteric 495 
microbiota, central and enteric nervous systems. Ann. Gastroenterol. 28, 203–209 (2015). 496 
19. Iyer, L. M., Aravind, L., Coon, S. L., Klein, D. C. & Koonin, E. V. Evolution of cell–cell signaling in animals: 497 
did late horizontal gene transfer from bacteria have a role? Trends Genet. 20, 292–299 (2004). 498 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 19 
20. Asano, Y. et al. Critical role of gut microbiota in the production of biologically active, free 499 
catecholamines in the gut lumen of mice. Am. J. Physiol.-Gastrointest. Liver Physiol. 303, G1288–G1295 500 
(2012). 501 
21. Kimura, I. et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G 502 
protein-coupled receptor 41 (GPR41). Proc. Natl. Acad. Sci. 108, 8030–8035 (2011). 503 
22. Grider, J. R. & Piland, B. E. The peristaltic reflex induced by short-chain fatty acids is mediated by 504 
sequential release of 5-HT and neuronal CGRP but not BDNF. Am. J. Physiol.-Gastrointest. Liver Physiol. 292, 505 
G429–G437 (2007). 506 
23. Vecsey, C. G. et al. Histone Deacetylase Inhibitors Enhance Memory and Synaptic Plasticity via CREB: 507 
CBP-Dependent Transcriptional Activation. J. Neurosci. 27, 6128–6140 (2007). 508 
24. Stefanko, D. P., Barrett, R. M., Ly, A. R., Reolon, G. K. & Wood, M. A. Modulation of long-term memory 509 
for object recognition via HDAC inhibition. Proc. Natl. Acad. Sci. 106, 9447–9452 (2009). 510 
25. Stecher, B. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric 511 
Pathogen Infection. Microbiol. Spectr. 3, (2015). 512 
26. Bekkering, P., Jafri, I., Overveld, F. J. van & Rijkers, G. T. The intricate association between gut microbiota 513 
and development of Type 1, Type 2 and Type 3 diabetes. Expert Rev. Clin. Immunol. 9, 1031–1041 (2013). 514 
27. Llorens, F. et al. MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at 515 
Early and Middle Stages of Braak Neurofibrillary Tangle Pathology. J. Mol. Neurosci. 63, 206–215 (2017). 516 
28. Attems, J., Jellinger, K. A. & Lintner, F. Alzheimer’s disease pathology influences severity and 517 
topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol. (Berl.) 110, 222–231 (2005). 518 
29. Herzig, M. C., Nostrand, W. E. V. & Jucker, M. Mechanism of Cerebral β-Amyloid Angiopathy: Murine and 519 
Cellular Models. Brain Pathol. 16, 40–54 (2006). 520 
30. Pistollato, F. et al. Role of gut microbiota and nutrients in amyloid formation and pathogenesis of 521 
Alzheimer disease. Nutr. Rev. 74, 624–634 (2016). 522 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 20 
31. Vangay, P., Ward, T., Gerber, J. S. & Knights, D. Antibiotics, Pediatric Dysbiosis, and Disease. Cell Host 523 
Microbe 17, 553–564 (2015). 524 
32. Muegge, B. D. et al. Diet Drives Convergence in Gut Microbiome Functions Across Mammalian 525 
Phylogeny and Within Humans. Science 332, 970–974 (2011). 526 
33. Delzenne, N. M., Neyrinck, A. M. & Cani, P. D. Modulation of the gut microbiota by nutrients with 527 
prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. S10 528 
(BioMed Central, 2011). doi:10.1186/1475-2859-10-S1-S10 529 
34. Rosenfeld, C. S. Microbiome Disturbances and Autism Spectrum Disorders. Drug Metab. Dispos. 43, 530 
1557–1571 (2015). 531 
35. Tilg, H. & Moschen, A. R. Microbiota and diabetes: an evolving relationship. Gut 63, 1513–1521 (2014). 532 
36. Galloway, S., Takechi, R., Pallebage-Gamarallage, M. M., Dhaliwal, S. S. & Mamo, J. C. Amyloid-β 533 
colocalizes with apolipoprotein B in absorptive cells of the small intestine. Lipids Health Dis. 8, 46 (2009). 534 
37. Galloway, S., Jian, L., Johnsen, R., Chew, S. & Mamo, J. C. L. β-Amyloid or its precursor protein is found in 535 
epithelial cells of the small intestine and is stimulated by high-fat feeding. J. Nutr. Biochem. 18, 279–284 536 
(2007). 537 
38. Jiang, C., Li, G., Huang, P., Liu, Z. & Zhao, B. The Gut Microbiota and Alzheimer’s Disease. J. Alzheimers 538 
Dis. 58, 1–15 (2017). 539 
39. Wu, S.-C., Cao, Z.-S., Chang, K.-M. & Juang, J.-L. Intestinal microbial dysbiosis aggravates the progression 540 
of Alzheimer’s disease in Drosophila. Nat. Commun. 8, 24 (2017). 541 
40. Schwartz, K. & Boles, B. R. Microbial amyloids – functions and interactions within the host. Curr. Opin. 542 
Microbiol. 16, 93–99 (2013). 543 
41. Oli, M. W. et al. Functional amyloid formation by Streptococcus mutans. Microbiology 158, 2903–2916 544 
(2012). 545 
42. Morales, R., Moreno-Gonzalez, I. & Soto, C. Cross-Seeding of Misfolded Proteins: Implications for 546 
Etiology and Pathogenesis of Protein Misfolding Diseases. PLOS Pathog. 9, e1003537 (2013). 547 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 21 
43. Friedland, R. P. Mechanisms of Molecular Mimicry Involving the Microbiota in Neurodegeneration. J. 548 
Alzheimers Dis. 45, 349–362 (2015). 549 
44. Asti, A. & Gioglio, L. Can a Bacterial Endotoxin be a Key Factor in the Kinetics of Amyloid Fibril 550 
Formation? J. Alzheimers Dis. 39, 169–179 (2014). 551 
45. Hornig, M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr. 552 
Opin. Rheumatol. 25, 488–795 (2013). 553 
46. Ano, Y., Sakudo, A. & Onodera, H. N. and T. Uptake and Dynamics of Infectious Prion Protein in the 554 
Intestine. Protein & Peptide Letters (2009). Available at: http://www.eurekaselect.com/84082/article. 555 
(Accessed: 14th November 2018) 556 
47. Yoshioka, H. et al. Immunohistochemical examination of Peyer’s patches in senescence-accelerated 557 
mice. Autoimmunity 8, 25–35 (1990). 558 
48. Hufnagel, D. A., Tükel, Ç. & Chapman, M. R. Disease to Dirt: The Biology of Microbial Amyloids. PLOS 559 
Pathog. 9, e1003740 (2013). 560 
49. Aziz, Q., Doré, J., Emmanuel, A., Guarner, F. & Quigley, E. M. M. Gut microbiota and gastrointestinal 561 
health: current concepts and future directions. Neurogastroenterol. Motil. 25, 4–15 (2013). 562 
50. Mitew, S., Kirkcaldie, M. T. K., Dickson, T. C. & Vickers, J. C. Altered synapses and gliotransmission in 563 
Alzheimer’s disease and AD model mice. Neurobiol. Aging 34, 2341–2351 (2013). 564 
51. Paula-Lima, A. C., Brito-Moreira, J. & Ferreira, S. T. Deregulation of excitatory neurotransmission 565 
underlying synapse failure in Alzheimer’s disease. J. Neurochem. 126, 191–202 (2013). 566 
52. Bienenstock, J., Kunze, W. & Forsythe, P. Microbiota and the gut–brain axis. Nutr. Rev. 73, 28–31 (2015). 567 
53. Short-chain fatty acids in control of body weight and insulin sensitivity | Nature Reviews Endocrinology. 568 
Available at: https://www-nature-com.ezproxy.library.tufts.edu/articles/nrendo.2015.128. (Accessed: 15th 569 
November 2018) 570 
54. Rocha, N. P., de Miranda, A. S. & Teixeira, A. L. Insights into Neuroinflammation in Parkinson’s Disease: 571 
From Biomarkers to Anti-Inflammatory Based Therapies. BioMed Res. Int. 2015, 628192 (2015). 572 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 22 
55. Wong, Y. C. & Krainc, D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic 573 
strategies. Nat. Med. 23, 1–13 (2017). 574 
56. Gold, A., Turkalp, Z. T. & Munoz, D. G. Enteric alpha-synuclein expression is increased in Parkinson’s 575 
disease but not Alzheimer’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 28, 237–240 (2013). 576 
57. Shannon, K. M. et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov. 577 
Disord. 27, 709–715 (2012). 578 
58. Böttner, M. et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous 579 
system. Neurobiol. Dis. 48, 474–480 (2012). 580 
59. Hasegawa, M. et al. Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions. J. Biol. 581 
Chem. 277, 49071–49076 (2002). 582 
60. Klein, C. & Westenberger, A. Genetics of Parkinson’s Disease. Cold Spring Harb. Perspect. Med. 2, 583 
a008888 (2012). 584 
61. Brundin, P., Ma, J. & Kordower, J. H. How strong is the evidence that Parkinson’s disease is a prion 585 
disorder? Curr. Opin. Neurol. 29, 459–466 (2016). 586 
62. Braak, H., de Vos, R. A. I., Bohl, J. & Del Tredici, K. Gastric α-synuclein immunoreactive inclusions in 587 
Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. 588 
Lett. 396, 67–72 (2006). 589 
63. Hilton, D. et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of 590 
Parkinson’s disease. Acta Neuropathol. (Berl.) 127, 235–241 (2014). 591 
64. Dutkiewicz, J. et al. Small intestine dysfunction in Parkinson’s disease. J. Neural Transm. 122, 1659–1661 592 
(2015). 593 
65. Sakakibara, R. et al. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J Neurol 594 
Neurosurg Psychiatry 74, 268–272 (2003). 595 
66. Gao, X., Chen, H., Schwarzschild, M. A. & Ascherio, A. A Prospective Study of Bowel Movement 596 
Frequency and Risk of Parkinson’s Disease. Am. J. Epidemiol. 174, 546–551 (2011). 597 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 23 
67. Lesser, G. T. Frequency of bowel movements and the future risk of Parkinson’s disease. (2018). 598 
68. Schwiertz, A. et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in 599 
Parkinson’s disease. Parkinsonism Relat. Disord. 50, 104–107 (2018). 600 
69. Chen, C.-H., Lin, C.-L. & Kao, C.-H. Irritable Bowel Syndrome Is Associated with an Increased Risk of 601 
Dementia: A Nationwide Population-Based Study. PLoS ONE 11, (2016). 602 
70. Lai, S.-W., Liao, K.-F., Lin, C.-L. & Sung, F.-C. Irritable bowel syndrome correlates with increased risk of 603 
Parkinson’s disease in Taiwan. Eur. J. Epidemiol. 29, 57–62 (2014). 604 
71. Tan, A. H. et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat. Disord. 605 
20, 535–540 (2014). 606 
72. Scheperjans, F. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. 607 
Disord. 30, 350–358 (2015). 608 
73. Lương, K. v q & Nguyễn, L. T. H. The Beneficial Role of Thiamine in Parkinson Disease. CNS Neurosci. 609 
Ther. 19, 461–468 (2013). 610 
74. Liu, J. et al. Sodium butyrate exerts protective effect against Parkinson’s disease in mice via stimulation 611 
of glucagon like peptide-1. J. Neurol. Sci. 381, 176–181 (2017). 612 
75. Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson’s disease: diagnosis 613 
and management. Lancet Neurol. 5, 235–245 (2006). 614 
76. Adjei, A. A., Christian, M. & Ivy, P. Novel Designs and End Points for Phase II Clinical Trials. Clin. Cancer 615 
Res. 15, 1866–1872 (2009). 616 
77. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 617 
711–716 (2004). 618 
78. Alcendor, D. J., Charest, A. M., Zhu, W. Q., Vigil, H. E. & Knobel, S. M. Infection and upregulation of 619 
proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus. J. 620 
Neuroinflammation 9, 95 (2012). 621 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 24 
79. Alcendor, D. J. et al. Neurovascular unit on a chip: implications for translational applications. Stem Cell 622 
Res. Ther. 4 Suppl 1, S18 (2013). 623 
80. Santaguida, S. et al. Side by side comparison between dynamic versus static models of blood–brain 624 
barrier in vitro: A permeability study. Brain Res. 1109, 1–13 (2006). 625 
81. Jamieson, J. J., Searson, P. C. & Gerecht, S. Engineering the human blood-brain barrier in vitro. J. Biol. 626 
Eng. 11, (2017). 627 
82. Cucullo, L., Hossain, M., Puvenna, V., Marchi, N. & Janigro, D. The role of shear stress in Blood-Brain 628 
Barrier endothelial physiology. BMC Neurosci. 12, 40 (2011). 629 
83. Haller, D. et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial 630 
cell/leucocyte co-cultures. Gut 47, 79–87 (2000). 631 
84. Kimura, H., Yamamoto, T., Sakai, H., Sakai, Y. & Fujii, T. An integrated microfluidic system for long-term 632 
perfusion culture and on-line monitoring of intestinal tissue models. Lab. Chip 8, 741–746 (2008). 633 
85. Sung, J. H., Yu, J., Luo, D., Shuler, M. L. & March, J. C. Microscale 3-D hydrogel scaffold for biomimetic 634 
gastrointestinal (GI) tract model. Lab. Chip 11, 389–392 (2011). 635 
86. Kim, H. J., Li, H., Collins, J. J. & Ingber, D. E. Contributions of microbiome and mechanical deformation to 636 
intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl. Acad. Sci. U. S. A. 113, 637 
E7–E15 (2016). 638 
87. Kim, H. J. & Ingber, D. E. Gut-on-a-Chip microenvironment induces human intestinal cells to undergo 639 
villus differentiation. Integr. Biol. 5, 1130–1140 (2013). 640 
88. Herland, A. et al. Distinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 641 
3D Human Blood-Brain Barrier on a Chip. PLoS ONE 11, (2016). 642 
89. Shin, W. & Kim, H. J. Intestinal barrier dysfunction orchestrates the onset of inflammatory host–643 
microbiome cross-talk in a human gut inflammation-on-a-chip. Proc. Natl. Acad. Sci. 115, E10539–E10547 644 
(2018). 645 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 25 
90. Wang, Y. I., Abaci, H. E. & Shuler, M. L. Microfluidic blood–brain barrier model provides in vivo-like 646 
barrier properties for drug permeability screening. Biotechnol. Bioeng. 114, 184–194 (2017). 647 
91. Ahmed, M., Puzan, M. & Koppes, D. A. Gut-Brain-Axis on a Chip: A Microfluidic Model of the 648 
Enteroendocrine-Enteric Nervous System Interface. 1 649 
92. Lee, S. Y. & Sung, J. H. Gut-liver on a chip toward an in vitro model of hepatic steatosis. Biotechnol. 650 
Bioeng. 115, 2817–2827 (2018). 651 
93. Choe, A., Ha, S. K., Choi, I., Choi, N. & Sung, J. H. Microfluidic Gut-liver chip for reproducing the first pass 652 
metabolism. Biomed. Microdevices 19, 4 (2017). 653 
94. Mochel, J. P. et al. Intestinal Stem Cells to Advance Drug Development, Precision, and Regenerative 654 
Medicine: A Paradigm Shift in Translational Research. AAPS J. 20, 17 (2017). 655 
95. Kingsbury, D. D. et al. Optimizing the Development and Characterization of Canine Small Intestinal Crypt 656 
Organoids as a Research Model. Gastroenterology 152, S353 (2017). 657 
96. Adult Canine Intestinal Derived Organoids: A Novel In Vitro System for Translational Research in 658 
Comparative Gastroenterology | bioRxiv. Available at: https://www.biorxiv.org/content/10.1101/466409v1. 659 
(Accessed: 25th January 2019) 660 
97. Flint, H. J. Obesity and the gut microbiota. J. Clin. Gastroenterol. 45 Suppl, S128-132 (2011). 661 
98. Ravussin, Y. et al. Responses of Gut Microbiota to Diet Composition and Weight Loss in Lean and Obese 662 
Mice. Obes. Silver Spring Md 20, (2012). 663 
99. Perlman, R. L. Mouse models of human disease. Evol. Med. Public Health 2016, 170–176 (2016). 664 
100. Martignoni, M., Groothuis, G. M. M. & Kanter, R. de. Species differences between mouse, rat, dog, 665 
monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. 666 
Toxicol. 2, 875–894 (2006). 667 
101. Anderson, S., Luffer-Atlas, D. & Knadler, M. P. Predicting Circulating Human Metabolites: How Good Are 668 
We? Chem. Res. Toxicol. 22, 243–256 (2009). 669 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 26 
102. Olson, H. et al. Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals. Regul. Toxicol. 670 
Pharmacol. 32, 56–67 (2000). 671 
103. Ghaisas, S., Maher, J. & Kanthasamy, A. Gut microbiome in health and disease: Linking the microbiome–672 
gut–brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. 673 
Pharmacol. Ther. 158, 52–62 (2016). 674 
104. Attems, J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible 675 
pathomechanisms. Acta Neuropathol. (Berl.) 110, 345–359 (2005). 676 
105. Transgenic Mouse Models of Alzheimer’s Disease - Elder - 2010 - Mount Sinai Journal of Medicine: A 677 
Journal of Translational and Personalized Medicine - Wiley Online Library. Available at: 678 
https://onlinelibrary.wiley.com/doi/abs/10.1002/msj.20159. (Accessed: 27th November 2018) 679 
106. Götz, J., Ittner, L. M., Schonrock, N. & Cappai, R. An update on the toxicity of Aβ in Alzheimer’s disease. 680 
Neuropsychiatr. Dis. Treat. 4, 1033–1042 (2008). 681 
107. Martin, S. B., Dowling, A. L. . & Head, E. Therapeutic Interventions Targeting Beta Amyloid Pathogenesis 682 
in an Aging Dog Model. Curr. Neuropharmacol. 9, 651–661 (2011). 683 
108. Sun, T. & Hevner, R. F. Growth and folding of the mammalian cerebral cortex: from molecules to 684 
malformations. Nat. Rev. Neurosci. 15, 217–232 (2014). 685 
109. Head, E. A canine model of human aging and Alzheimer’s disease. Biochim. Biophys. Acta 1832, 1384–686 
1389 (2013). 687 
110. Cummings, B. J., Pike, C. J., Shankle, R. & Cotman, C. W. Beta-amyloid deposition and other measures of 688 
neuropathology predict cognitive status in Alzheimer’s disease. Neurobiol. Aging 17, 921–933 (1996). 689 
111. Kol, A. et al. Companion animals: Translational scientist’s new best friends. Sci. Transl. Med. 7, 308ps21 690 
(2015). 691 
112. Axelsson, E. et al. The genomic signature of dog domestication reveals adaptation to a starch-rich diet. 692 
Nature 495, 360–364 (2013). 693 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 27 
113. Patronek, G. J., Waters, D. J. & Glickman, L. T. Comparative longevity of pet dogs and humans: 694 
implications for gerontology research. J. Gerontol. A. Biol. Sci. Med. Sci. 52, B171-178 (1997). 695 
114. Davis, P. R. & Head, E. Prevention approaches in a preclinical canine model of Alzheimer’s disease: 696 
benefits and challenges. Front. Pharmacol. 5, (2014). 697 
115. Pugliese, M. et al. Magnetic resonance imaging of cerebral involutional changes in dogs as markers of 698 
aging: An innovative tool adapted from a human visual rating scale. Vet. J. 186, 166–171 (2010). 699 
116. Rofina, J. E. et al. Cognitive disturbances in old dogs suffering from the canine counterpart of 700 
Alzheimer’s disease. Brain Res. 1069, 216–226 (2006). 701 
117. Su, M.-Y. et al. A longitudinal study of brain morphometrics using serial magnetic resonance imaging 702 
analysis in a canine model of aging. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 389–397 (2005). 703 
118. Borràs, D., Ferrer, I. & Pumarola, M. Age-related Changes in the Brain of the Dog. Vet. Pathol. 36, 202–704 
211 (1999). 705 
119. Ishihara, T. et al. Immunohistochemical and immunoelectron microscopical characterization of 706 
cerebrovascular and senile plaque amyloid in aged dogs’ brains. Brain Res. 548, 196–205 (1991). 707 
120. Colle, M.-A. et al. Vascular and parenchymal Aβ deposition in the aging dog: correlation with behavior. 708 
Neurobiol. Aging 21, 695–704 (2000). 709 
121. Insua, D. et al. Expression of p75 NTR, a Marker for Basal Forebrain Cholinergic Neurons, in Young and 710 
Aged Dogs with or without Cognitive Dysfunction Syndrome. J. Alzheimers Dis. 28, 291–296 (2012). 711 
122. Schütt, T. et al. Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer’s Disease: 712 
A Translational Study of Neuropathological and Inflammatory Markers. J. Alzheimers Dis. 52, 433–449 (2016). 713 
123. Schütt, T., Toft, N. & Berendt, M. Cognitive Function, Progression of Age-related Behavioral Changes, 714 
Biomarkers, and Survival in Dogs More Than 8 Years Old. J. Vet. Intern. Med. 29, 1569–1577 (2015). 715 
124. deLahunta, A. & Averill, D. R. Hereditary cerebellar cortical and extrapyramidal nuclear abiotrophy in 716 
Kerry Blue Terriers. J. Am. Vet. Med. Assoc. 168, 1119–1124 (1976). 717 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 28 
125. O’Brien, D. P. Genetic Mapping of Canine Multiple System Degeneration and Ectodermal Dysplasia Loci. 718 
J. Hered. 96, 727–734 (2005). 719 
126. Montgomery, D. L. & Storts, R. W. Hereditary Striatonigral and Cerebello-Olivary Degeneration of the 720 
Kerry Blue Terrier. I. Gross and Light Microscopic Central Nervous System Lesions. Vet. Pathol. 20, 143–159 721 
(1983). 722 
127. Coelho, L. P. et al. Similarity of the dog and human gut microbiomes in gene content and response to 723 
diet. Microbiome 6, 72 (2018). 724 
128. Terao, M. et al. Avian and canine aldehyde oxidases. Novel insights into the biology and evolution of 725 
molybdo-flavoenzymes. J. Biol. Chem. 281, 19748–19761 (2006). 726 
129. Garattini, E., Mendel, R., Romão, M. J., Wright, R. & Terao, M. Mammalian molybdo-flavoenzymes, an 727 
expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem. J. 372, 728 
15–32 (2003). 729 
130. Zhang, L., Fitzloff, J. F., Engel, L. C. & Cook, C. S. Species difference in stereoselective involvement of 730 
CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica Fate Foreign Compd. Biol. Syst. 31, 73–83 731 
(2001). 732 
131. Alkasir, R., Li, J., Li, X., Jin, M. & Zhu, B. Human gut microbiota: the links with dementia development. 733 
Protein Cell 8, 90–102 (2017). 734 
132. Lerner, A., Neidhöfer, S. & Matthias, T. The Gut Microbiome Feelings of the Brain: A Perspective for Non-735 
Microbiologists. Microorganisms 5, (2017). 736 
133. Scott, K. P., Antoine, J.-M., Midtvedt, T. & van Hemert, S. Manipulating the gut microbiota to maintain 737 
health and treat disease. Microb. Ecol. Health Dis. 26, (2015). 738 
134. Kossoff, E. H. et al. Optimal clinical management of children receiving the ketogenic diet: 739 
Recommendations of the International Ketogenic Diet Study Group. Epilepsia 50, 304–317 (2009). 740 
135. Erdő, F., Denes, L. & de Lange, E. Age-associated physiological and pathological changes at the blood–741 
brain barrier: A review. J. Cereb. Blood Flow Metab. 37, 4–24 (2017). 742 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 29 
136. Barañano, K. W. & Hartman, A. L. The Ketogenic Diet: Uses in Epilepsy and Other Neurologic Illnesses. 743 
Curr. Treat. Options Neurol. 10, 410–419 (2008). 744 
137. The Ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res. 68, 145–180 (2006). 745 
138. Lund, T. M., Risa, Ø., Sonnewald, U., Schousboe, A. & Waagepetersen, H. S. Availability of 746 
neurotransmitter glutamate is diminished when β-hydroxybutyrate replaces glucose in cultured neurons. J. 747 
Neurochem. 110, 80–91 (2009). 748 
139. Erecińska, M., Nelson, D., Daikhin, Y. & Yudkoff, M. Regulation of GABA level in rat brain synaptosomes: 749 
fluxes through enzymes of the GABA shunt and effects of glutamate, calcium, and ketone bodies. J. 750 
Neurochem. 67, 2325–2334 (1996). 751 
140. Gillette-Guyonnet, S. et al. Commentary on “A roadmap for the prevention of dementia II. Leon Thal 752 
Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of 753 
Alzheimer’s disease. Alzheimers Dement. 5, 114–121 (2009). 754 
141. Mihaylova, M. M. et al. Fasting Activates Fatty Acid Oxidation to Enhance Intestinal Stem Cell Function 755 
during Homeostasis and Aging. Cell Stem Cell 22, 769-778.e4 (2018). 756 
142. Law, T. H. et al. A randomised trial of a medium-chain TAG diet as treatment for dogs with idiopathic 757 
epilepsy. Br. J. Nutr. 114, 1438–1447 (2015). 758 
143. Studzinski, C. M. et al. Induction of ketosis may improve mitochondrial function and decrease steady-759 
state amyloid-β precursor protein (APP) levels in the aged dog. Brain Res. 1226, 209–217 (2008). 760 
144. Milgram, N. W. et al. Learning ability in aged beagle dogs is preserved by behavioral enrichment and 761 
dietary fortification: a two-year longitudinal study. Neurobiol. Aging 26, 77–90 (2005). 762 
145. Barrett, E., Ross, R. P., O’Toole, P. W., Fitzgerald, G. F. & Stanton, C. γ-Aminobutyric acid production by 763 
culturable bacteria from the human intestine. J. Appl. Microbiol. 113, 411–417 (2012). 764 
146. Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R. & Ingber, N. GABAergic Function in Alzheimer’s 765 
Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and 766 
Psychological Symptoms of Dementia. Can. J. Psychiatry 49, 439–453 (2004). 767 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
 30 
147. Gareau, M. G. et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 60, 307–768 
317 (2011). 769 
148. Wang, T. et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and 770 
psychological abnormalities in rats. Benef. Microbes 6, 707–717 (2015). 771 
149. Liang, S. et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and 772 
biochemical aberrations caused by chronic restraint stress. Neuroscience 310, 561–577 (2015). 773 
150. Distrutti, E. et al. Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene 774 
Expression and Ameliorates the Age-Related Deficit in LTP. PLOS ONE 9, e106503 (2014). 775 
151. Akbari, E. et al. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in 776 
Alzheimer’s Disease: A Randomized, Double-Blind and Controlled Trial. Front. Aging Neurosci. 8, (2016). 777 
152. The R&D Cost of a New Medicine. Available at: https://www.ohe.org/publications/rd-cost-new-778 
medicine#. (Accessed: 15th November 2018) 779 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 28 January 2019                   
